Levonantradol

Из Википедије, слободне енциклопедије
Levonantradol
Levonantradol.svg
IUPAC ime
[(6S,6aR,9R,10aR)- 9-hidroksi- 6-metil- 3-[(2R)-5-fenilpentan- 2-il]oksi- 5,6,6a,7,8,9,10,10a-oktahidrofenantridin- 1-il] acetat
Identifikatori
CAS broj 71048-87-8 ДаY
ATC kod none
PubChem CID 5361881
ChemSpider 4514867 ДаY
UNII 03S640ADSK ДаY
Hemijski podaci
Formula C27H35NO4
Molarna masa 437,571 g/mol
  (verify)

Levonantradol (CP 50,556-1) je sintetički kanabinoidni analog dronabinola (Marinola). Ovaj lek je razvila kompanija Pfizer tokom 1980-tih. On je oko 30x puta potentniji od THC, i manifestuje antiemetske i analgetske efekte putem aktivacije CB1 i CB2 kanabinoidnih receptora.[1] Levonantradol trenutno nije u upotrebi jer su dronabinol i nabilon primenljivi na veći broj oboljenja. On nalazi široku primenu u istraživanju potencijalne terapeutske primene kanabinoida.[2][3][4]

Vidi još[уреди]

Reference[уреди]

  1. Little PJ, et al. Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. Journal of Pharmacology and Experimental Therapeutics 1988; 247:1046–1051.
  2. Tramer MR, et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. British Medical Journal 2001 Jul 7;323(7303):16-21.
  3. Campbell FA, et al. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. British Medical Journal. 2001 Jul 7;323(7303):13-6.
  4. Ben Amar M. Cannabinoids in medicine: A review of their therapeutic potential. Journal of Ethnopharmacology. 2006 Apr 21;105(1-2):1-25.

Literatura[уреди]

  • Childers, SR (2006 Mar 10). „Activation of G-proteins in brain by endogenous and exogenous cannabinoids.”. The AAPS journal. 8 (1): E112—7. doi:10.1208/aapsj080113. PMC 2751429Слободан приступ. PMID 16584117. 
  • Hosking, R.D.; Zajicek, J.P. (2008). „Therapeutic potential of cannabis in pain medicine”. British Journal of Anaesthesia. 101 (1): 59—68. 
  • McCarthy, LE; Borison, HL (1981 Aug-Sep). „Antiemetic activity of N-methyllevonantradol and nabilone in cisplatin-treated cats.”. Journal of clinical pharmacology. 21 (8–9 Suppl): 30S—37S. PMID 6271834. 
  • Milewich, L; Gant, NF; Schwarz, BE; Chen, GT; MacDonald, PC (1979 Mar 15). „5 alpha-Reductase activity in human placenta.”. American journal of obstetrics and gynecology. 133 (6): 611—7. PMID 34324. 

Spoljašnje veze[уреди]